Language selection

Government of Canada / Gouvernement du Canada

Search

Updated recommendations on the use of herpes zoster vaccines .: HP40-212/2018E-PDF

"The need for this updated National Advisory Committee on Immunization (NACI) Advisory Committee Statement on the Use of Herpes Zoster (HZ) Vaccines was triggered by evidence on a newly authorized Recombinant subunit Zoster Vaccine (RZV) vaccine, Shingrix®, indicated for the prevention of HZ in individuals 50 years of age and older. The primary objective of this statement is to review current evidence and develop guidance on the use of Shingrix®, as well as to provide guidance on whether the previously authorized Live Zoster Vaccine (LZV), Zostavax®II, and/or the recently authorized RZV should be offered to Canadians ≥50 years of age and older"--Introd., p. 6.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.853982&sl=0

Publication information
Department/Agency
  • Public Health Agency of Canada. Infectious Disease Prevention and Control Branch.
TitleUpdated recommendations on the use of herpes zoster vaccines .
Variant title
  • At head of title: Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI)
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Issued also in French under title: Recommandations à jour sur l’utilisation des vaccins contre le zona.
  • Includes bibliographic references: p. 63-72.
Publishing information
  • Ottawa : Public Health Agency of Canada,2018.
Description177 p. : col. charts.
ISBN9780660258522
Catalogue number
  • HP40-212/2018E-PDF
Departmental catalogue numberPub.: 170531
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details

Report a problem or mistake on this page
Date modified: